1960 Scientists in the Institute of Microbiology and Virology of The Latvian Academy of Sciences discovers that viruses recovered from the intestines of healthy children are capable of destroying tumours.
1965 The Cancer Virotherapy Laboratory was established at the Institute to study this virus phenomenon further under the leadership of Aina Muceniece.
1968 The Ministry of Health Protection (the competent regulatory authority) approved the start of RIGVIR® clinical trials in the 2nd Department of the Oncology Dispensary and the 18th Chemotherapy Department of the Pauls Stradiņš Clinical Hospital in Riga.
1985 Extended RIGVIR® clinical trials started in three Riga hospitals: Latvian Oncology Center (the former Oncology Dispensary), the P. Stradiņš Clinical Hospital, Riga Stradiņš University Institute of Dentistry (at that time AML), and the Saratov Oncology Hospital (Russia). At that time the studies were, however, neither randomised nor double-blind. Over 700 patients in were enrolled in these clinical trials until 1991.
1987 Part of the multicenter and multinational Rigvir clinical trials also start at the All-Union Cancer Research Center in Moscow.
2004 RIGVIR® is registered by the State Agency of Medicines of the Republic of Latvia, thus Rigvir becomes the first approved oncolytic virotherapy medication.
2008 International Virotherapy Center is established in Riga, Latvia. Its mission is to provide virotherapy information for every cancer patient who wants it.
2011 Oncolytic virotherapy with RIGVIR® is included in the list of reimbursable state-funded medical products in Latvia for skin melanoma patients.
2015 Oncolytic virotherapy with RIGVIR® is included in the clinical guidelines of the National Health Service of Latvia entitled “Diagnostics, treatment and dynamic observation of skin cancer and melanoma”.
2016 The first cancer virotherapy excellence center, the Global Virotherapy Cancer Clinic, is opened in Jūrmala, Latvia.
2016 The RIGVIR® marketing authorization holder receives a grant from “Horizon 2020” to support activities for registration in the European Union.
2017 RIGVIR® receives special recommendations for medication registration in EU from European Medicines agency (EMA).
2017 RIGVIR® manufacturer receives Seal of Excellence award given by European Commission.
2017 RIGVIR® manufacturer receives intellectual property award “WIPO Enterprise Trophy”.